MedTrace Logo

A Study to See How Safe a New Medicine (NNC6022-0004) is in Healthy People and People Living With Obesity

NCT07693868 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 128

Last updated 2026-08-19

No results posted yet for this study

Summary

This study is being done to look at the efficacy single and multiple ascending dose study investigating safety, tolerability, pharmacokinetics, food effect and target engagement in healthy adults including a single cohort in adults living with obesity. Participants will either get NNC6022-0004, (the treatment being tested) or Placebo (a treatment that has no active medicine in it) and which treatment participants get is decided by chance.

Conditions

  • Obesity
  • Elevated High-sensitivity C-reactive Protein (hsCRP)

Interventions

DRUG

NNC6022-0004

Participants will receive single dose of NNC6022-0004 administered orally in capsule form.

DRUG

Placebo

Participants will receive placebo matched to NNC6022-0004 administered orally in capsule form.

Sponsors & Collaborators

Principal Investigators

  • Clinical Transparency dept. 2834 · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-07-06
Primary Completion
2027-08-01
Completion
2027-08-01
FDA Drug
Yes

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07693868 on ClinicalTrials.gov